Fiskars Oyj Abp financials
Fiskars Oyj Abp
Country: FI Reporting currency: EUR Latest annual report: 2025-12-31
LEI:
743700BKTW4EQIVKYY42 Financial statements
(EUR, as reported — unscaled; 101 line items across 2 annual periods)
| Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Revenue | €1.14B | €1.16B |
| Cost of sales | €605.1M | €640.0M |
| Gross profit | €535.1M | €517.0M |
| Other income | €20.9M | €5.7M |
| Administrative expenses | €127.1M | €132.1M |
| Operating profit (EBIT) | €38.1M | €37.1M |
| Net finance income / (cost) | -€30.0M | -€25.2M |
| Profit before tax | €12.5M | €18.5M |
| Income tax expense | €2.9M | -€8.9M |
| Profit for the year | €9.6M | €27.3M |
| — attributable to owners | €9.3M | €27.1M |
| — attributable to NCI | €200.0K | €300.0K |
| Total comprehensive income | -€11.2M | €36.0M |
| Per share | ||
| Basic EPS | €0.12 | €0.33 |
| Diluted EPS | €0.12 | €0.33 |
| Free cash flow / share | €0.72 | €0.72 |
| Cash flow statement | ||
| Cash generated from operations | €128.2M | €145.4M |
| Net cash from operating activities | €100.8M | €112.3M |
| Income taxes paid | €8.5M | €12.1M |
| Net cash from investing activities | -€41.8M | -€49.5M |
| Purchase of PP&E (capex) | €43.5M | €52.5M |
| Net cash from financing activities | -€37.1M | -€128.6M |
| Dividends paid | €67.9M | €63.3M |
| Lease liability payments | €40.8M | €40.6M |
| Net change in cash | €21.9M | -€65.8M |
| Balance sheet | ||
| Total assets | €1.64B | €1.71B |
| Non-current assets | €1.00B | €1.07B |
| Property, plant & equipment | €165.9M | €167.4M |
| Right-of-use assets | €115.6M | €138.2M |
| Intangible assets & goodwill | €218.1M | €225.9M |
| Current assets | €639.5M | €641.3M |
| Inventories | €322.9M | €330.7M |
| Trade & other receivables | €178.3M | €188.9M |
| Cash & equivalents | €82.6M | €60.8M |
| Total equity | €714.7M | €796.5M |
| — attributable to owners | €710.4M | €792.2M |
| Non-controlling interests | €4.3M | €4.3M |
| Non-current liabilities | €478.1M | €502.1M |
| Long-term borrowings | €330.6M | €331.0M |
| Lease liabilities (non-current) | €88.3M | €113.9M |
| Current liabilities | €449.4M | €412.5M |
| Lease liabilities (current) | €37.5M | €33.6M |
| Deferred tax liabilities | €40.9M | €36.9M |
| Derived metrics | ||
| Free cash flow | €57.3M | €59.8M |
| Operating margin | 3.3% | 3.2% |
| Net margin | 0.8% | 2.4% |
| Return on equity | 1.3% | 3.4% |
| Cash conversion ratio | 10.50× | 4.11× |
| Capex coverage | 2.32× | 2.14× |
| Other reported items | ||
| Adjustments For Decrease Increase In Inventories | -€11.2M | €46.2M |
| Adjustments For Decrease Increase In Trade and Other Receivables | €4.7M | -€14.1M |
| Adjustments For Depreciation and Amortisation Expense and Impairment Loss Reversal of Impairment Loss Recognised In Profit Or Loss | €84.1M | €82.5M |
| Adjustments For Finance Income Cost | -€30.1M | -€25.1M |
| Adjustments For Gains Losses On Change In Fair Value Less Costs To Sell Biological Assets | €4.5M | €6.5M |
| Adjustments For Increase Decrease In Trade and Other Payables | -€9.7M | -€3.5M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | €26.6M | -€1.0M |
| Cash Flows From Used In Increase Decrease In Current Borrowings | €73.9M | -€25.4M |
| Cash Flows From Used In Operations Before Changes In Working Capital | €144.5M | €116.7M |
| Comprehensive Income Attributable To Noncontrolling Interests | €0 | €500.0K |
| Comprehensive Income Attributable To Owners of Parent | -€11.2M | €35.5M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €139.5M | €76.1M |
| Current Loans and Receivables | €100.0K | €0 |
| Current Provisions | €1.8M | €3.5M |
| Current Tax Assets Current | €2.8M | €7.6M |
| Current Tax Liabilities Current | €7.1M | €14.4M |
| Deferred Tax Assets | €53.1M | €48.8M |
| Dividends Proposed Or Declared Before Financial Statements Authorised For Issue But Not Recognised As Distribution To Owners Per Share | €0.84 | — |
| Dividends Received Classified As Investing Activities | €200.0K | €100.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€100.0K | -€600.0K |
| Equity and Liabilities | €1.64B | €1.71B |
| Finance Costs Paid Classified As Operating Activities | €26.6M | €29.4M |
| Finance Income Received Classified As Operating Activities | €7.7M | €8.4M |
| Gains Losses On Fair Value Adjustment Biological Assets | €4.5M | €6.5M |
| Increase Decrease Through Sharebased Payment Transactions | €2.1M | €1.1M |
| Increase Decrease Through Transfers and Other Changes Equity | -€1.2M | €1.9M |
| Increase Decrease Through Treasury Share Transactions | -€3.6M | €200.0K |
| Intangible Assets Other Than Goodwill | €339.2M | €378.3M |
| Investment Property | €9.0M | €6.3M |
| Noncurrent Biological Assets | €62.3M | €57.8M |
| Noncurrent Financial Assets At Fair Value Through Profit Or Loss | €25.1M | €29.8M |
| Noncurrent Investments Other Than Investments Accounted For Using Equity Method | €3.5M | €3.5M |
| Noncurrent Provisions | €3.2M | €3.5M |
| Noncurrent Recognised Liabilities Defined Benefit Plan | €11.7M | €12.3M |
| Other Comprehensive Income | -€20.8M | €8.7M |
| Other Comprehensive Income Net of Tax Cash Flow Hedges | €800.0K | -€700.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | -€22.1M | €9.4M |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | €600.0K | €0 |
| Other Current Payables | €179.4M | €196.5M |
| Other Current Receivables | €52.7M | €53.3M |
| Other Expense By Function | €34.8M | €10.3M |
| Other Inflows Outflows of Cash Classified As Financing Activities | €1.3M | €100.0K |
| Other Inflows Outflows of Cash Classified As Investing Activities | €800.0K | €1.1M |
| Other Noncurrent Assets | €10.9M | €13.9M |
| Other Noncurrent Liabilities | €3.5M | €4.4M |
| Payments To Acquire Or Redeem Entitys Shares | €3.6M | €600.0K |
| Proceeds From Noncurrent Borrowings | €0 | €0 |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | €700.0K | €1.7M |
| Repayments of Noncurrent Borrowings | €0 | €200.0K |
| Research and Development Expense | €22.9M | €18.8M |
| Sales and Marketing Expense | €333.2M | €324.4M |
| Trade and Other Current Payables To Trade Suppliers | €84.1M | €88.4M |
Methodology
Every line item above is a fact tagged in Fiskars Oyj Abp's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.